10:23 AM EDT, 07/30/2024 (MT Newswires) -- Biogen (BIIB), Beckman Coulter, and Fujirebio said Tuesday they are partnering to potentially develop blood-based biomarkers for detecting tau pathology in the brain of Alzheimer's disease patients.

Financial details weren't disclosed.

The companies said they aim to create minimally invasive tests to stratify patients and monitor treatment responses, potentially supporting the development of new therapies for Alzheimer's.

Biogen will contribute clinical study data and biomarker research knowledge, while Beckman Coulter and Fujirebio will handle diagnostic development, manufacturing, and commercialization, the companies said.

Price: 214.71, Change: +0.28, Percent Change: +0.13